PIGMENTED VILLONODULAR SYNOVITIS
Clinical trials for PIGMENTED VILLONODULAR SYNOVITIS explained in plain language.
Never miss a new study
Get alerted when new PIGMENTED VILLONODULAR SYNOVITIS trials appear
Sign up with your email to follow new studies for PIGMENTED VILLONODULAR SYNOVITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for rare joint tumor and advanced cancers
Disease control OngoingThis study tests an experimental drug called vimseltinib in people with advanced solid tumors or a rare joint tumor called tenosynovial giant cell tumor (TGCT). The goal is to find the safest dose and see if the drug shrinks tumors or improves joint movement. About 120 adults wil…
Matched conditions: PIGMENTED VILLONODULAR SYNOVITIS
Phase: PHASE1, PHASE2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New drug shows promise for rare, painful joint tumors
Disease control OngoingThis study tests a new drug called ABSK021 (Pimicatinib) for people with tenosynovial giant cell tumor (TGCT), a rare but painful tumor that grows in and around joints. About 94 adults with tumors that cannot be removed by surgery will take either the drug or a placebo for 24 wee…
Matched conditions: PIGMENTED VILLONODULAR SYNOVITIS
Phase: PHASE3 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New pill could shrink rare joint tumors without surgery
Disease control OngoingThis study tests an experimental drug called vimseltinib for people with tenosynovial giant cell tumor (TGCT), a rare but painful joint tumor that can't be removed surgically. About 123 adults with moderate to severe pain or stiffness will receive either the drug or a placebo for…
Matched conditions: PIGMENTED VILLONODULAR SYNOVITIS
Phase: PHASE3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated May 14, 2026 12:01 UTC